DexCom, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results
February 25 2015 - 4:01PM
Business Wire
DexCom, Inc. (Nasdaq: DXCM) today reported its audited financial
results as of and for the quarter and fiscal year ended
December 31, 2014.
For the full-year ended December 31, 2014, product revenue
grew to $257.1 million, an increase of 64% from the $157.1 million
in product revenue reported for 2013, and total revenue grew to
$259.2 million, an increase of 62% from 2013. Product revenue grew
to $84.3 million for the fourth quarter of 2014, an increase of 64%
from the $51.3 million in product revenue reported for the
comparable period in 2013. Total fourth quarter 2014 revenue, which
included development grant and other revenue, grew to $84.3
million, an increase of 63% from the comparable period in 2013.
Product gross profit totaled $59.4 million and $174.8 million for
the three and twelve months ended December 31, 2014, compared
to a product gross profit of $34.1 million and $99.0 million for
the three and twelve months ended December 31, 2013. The
Company reported net income of $1.3 million, or $0.02 per share,
and a net loss of $22.4 million, or $0.30 per share, for the three
and twelve months ended December 31, 2014, compared to a net
loss of $2.6 million, or $0.04 per share, and $29.8 million, or
$0.42 per share, for the three and twelve months ended
December 31, 2013. The net loss for 2014 included $58.8
million in non-cash expenses, comprised primarily of share-based
compensation, depreciation, and amortization.
Total cost of sales for the twelve months ended
December 31, 2014 totaled $82.9 million compared to $59.9
million for 2013. The increase was primarily due to additional
product sales. Research and development expense totaled $69.4
million in 2014 compared to $44.8 million in 2013. Changes in
research and development expense included additional payroll costs,
consulting costs and $8.5 million in additional non-cash
share-based compensation. Selling, general and administrative
expense totaled $128.4 million in 2014 compared to $84.2 million in
2013, with the change primarily due to additional payroll costs,
commissions and $15.0 million in additional non-cash share-based
compensation. As of December 31, 2014, the Company had $83.6
million in cash, cash equivalents and marketable securities.
Conference Call
Management will hold a conference call today starting at 4:30
p.m. (Eastern Time). The conference call will be concurrently
webcast. The link to the webcast will be available on the DexCom,
Inc. website at www.dexcom.com by navigating to "Our Company," then
"Investor Relations," and then "Events and Webcasts," and will be
archived for future reference. To listen to the conference call,
please dial (888) 771-4371 (US/Canada) or (847) 585-4405
(International) and use the confirmation number "38766435"
approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is
developing and marketing continuous glucose monitoring systems for
ambulatory use by people with diabetes and by healthcare providers
in the hospital.
Cautionary Statement Regarding Forward Looking
Statements
DexCom is a medical device company with a limited operating
history. Successful commercialization of the company’s products is
subject to numerous risks and uncertainties, including a lack of
acceptance in the marketplace by physicians and people with
diabetes, the inability to manufacture products in commercial
quantities at an acceptable cost, possible delays in the company’s
development programs, the inability of people with diabetes to
receive reimbursement from third-party payors and inadequate
financial and other resources. Certain of these risks and
uncertainties, in addition to other risks, are more fully described
in the company's annual report on Form 10-K for the period ended
December 31, 2014, as filed with the Securities and Exchange
Commission on February 25, 2015.
DexCom, Inc. Consolidated Balance
Sheets (In millions—except par value data)
December 31, 2014 December 31, 2013 Assets
Current assets: Cash and cash equivalents $ 71.8 $ 43.2 Short-term
marketable securities, available-for-sale 11.8 11.4 Accounts
receivable, net 42.4 26.1 Inventory 16.0 9.0 Prepaid and other
current assets 3.9 3.4 Total current assets 145.9
93.1 Property and equipment, net 31.2 20.7 Restricted cash 1.0 1.0
Intangible assets, net 2.7 3.6 Goodwill 3.2 3.2 Other assets 0.6
0.9 Total assets $ 184.6 $ 122.5
Liabilities and stockholders’ equity Current liabilities:
Accounts payable and accrued liabilities $ 20.4 $ 14.1 Accrued
payroll and related expenses 17.2 15.1 Current portion of long-term
debt 2.3 2.2 Current portion of deferred revenue 0.7 0.7
Total current liabilities 40.6 32.1 Other liabilities 1.5
1.7 Long-term debt, net of current portion 2.3 4.6
Total liabilities 44.4 38.4 Commitments and contingencies
Stockholders’ equity: Preferred stock, $0.001 par value, 5.0 shares
authorized; no shares issued and outstanding at December 31, 2014
and December 31, 2013, respectively — — Common stock, $0.001 par
value, 100.0 authorized; 77.6 and 77.3 issued and outstanding,
respectively, at December 31, 2014; and 72.8 and 72.5 shares issued
and outstanding, respectively, at December 31, 2013 0.1 0.1
Additional paid-in capital 638.0 559.5 Accumulated other
comprehensive loss (0.1 ) (0.1 ) Accumulated deficit (497.8 )
(475.4 ) Total stockholders’ equity 140.2 84.1 Total
liabilities and stockholders’ equity $ 184.6 $ 122.5
DexCom, Inc. Consolidated Statements of
Operations (In millions—except per share data)
Three Months Ended December
31,
Twelve Months Ended December
31,
2014 2013 2014
2013 Product revenue $ 84.3 $ 51.3 $ 257.1 $
157.1 Development grant and other revenue — 0.4 2.1
2.9 Total revenue 84.3 51.7 259.2 160.0 Product cost
of sales 24.9 17.2 82.3 58.1 Development and other cost of sales —
0.4 0.6 1.8 Total cost of sales 24.9
17.6 82.9 59.9 Gross profit 59.4 34.1
176.3 100.1 Operating expenses Research and development 21.6 12.6
69.4 44.8 Selling, general and administrative 36.2 23.8
128.4 84.2 Total operating expenses 57.8
36.4 197.8 129.0 Operating income
(loss) 1.6 (2.3 ) (21.5 ) (28.9 ) Interest expense (0.2 ) (0.3 )
(0.8 ) (0.9 ) Income (loss) before income taxes 1.4 (2.6 ) (22.3 )
(29.8 ) Income tax expense 0.1 — 0.1 —
Net income (loss) $ 1.3 $ (2.6 ) $ (22.4 ) $ (29.8 )
Basic net income (loss) per share $ 0.02 $ (0.04 ) $ (0.30 )
$ (0.42 ) Shares used to compute basic net income (loss) per share
76.8 72.0 75.2 71.1 Diluted net income
(loss) per share $ 0.02 $ (0.04 ) $ (0.30 ) $ (0.42 ) Shares
used to compute diluted net income (loss) per share 81.7
72.0 75.2 71.1
DexCom, Inc.Steven R. PacelliExecutive Vice President, Strategy
and Corporate Development(858) 200-0200www.dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2023 to Apr 2024